Pibrentasvir is an NS5A inhibitor antiviral agent.[1] In the United States and Europe, it is approved for use with glecaprevir as the combination drug glecaprevir/pibrentasvir (trade name Mavyret in the US and Maviret in the EU) for the treatment of hepatitis C.[2][3] It is sold by Abbvie.
References
^Ng, Teresa I.; Krishnan, Preethi; Pilot-Matias, Tami; Kati, Warren; Schnell, Gretja; Beyer, Jill; Reisch, Thomas; Lu, Liangjun; Dekhtyar, Tatyana; Irvin, Michelle; Tripathi, Rakesh; Maring, Clarence; Randolph, John T.; Wagner, Rolf; Collins, Christine (2017). "In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir". Antimicrobial Agents and Chemotherapy. 61 (5): e02558–16. doi:10.1128/AAC.02558-16. PMC 5404558. PMID 28193664.
^Linda A. Johnson (August 3, 2017). "FDA OKs new drug to treat all forms of hepatitis C". Fox Business.
^"Maviret: EPAR – Summary for the public" (PDF). European Medicines Agency. 2017-08-17.
v
t
e
RNA virus antivirals (primarily J05, also S01AD and D06BB)
…early on for adverse effects. Glecaprevir-pibrentasvir – In a trial of 145 patients with genotype 2 infection without cirrhosis, glecaprevir-pibrentasvir for eight weeks resulted in an SVR rate of 98 …
… Glecaprevir-pibrentasvir – Glecaprevir-pibrentasvir is a potent, highly effective pangenotypic regimen. In a study of HIV/HCV-coinfected patients treated with glecaprevir-pibrentasvir, all of the 87 …
…results in SVR rates of approximately 98 to 99 percent . Glecaprevir-pibrentasvir – For treatment-naive patients, glecaprevir-pibrentasvir is given for eight weeks, regardless of the presence of cirrhosis …
…consists of 100 mg glecaprevir and 40 mg pibrentasvir. The daily dose consists of three tablets taken at the same time, administered with food. Glecaprevir-pibrentasvir can be used in patients with any degree …
…subtype. However, trials of glecaprevir-pibrentasvir do not indicate differential response by subtype. In one trial 8 or 12 weeks of glecaprevir-pibrentasvir in patients without cirrhosis, SVR rates were …
English Journal
Modeling-based response-guided therapy for chronic hepatitis C under glecaprevir/pibrentasvir may identify patients for ultra-short treatment duration.
Dasgupta S, Imamura M, Gorstein E, Nakahara T, Tsuge M, Churkin A, Yardeni D, Etzion O, Uprichard SL, Barash D, Cotler SJ, Dahari H, Chayama K.
The Journal of infectious diseases. 2020 May;().
We recently showed in a proof-of-concept study that real-time modeling-based response-guided therapy (RGT) can shorten hepatitis C virus (HCV) treatment duration with sofosbuvir/velpatasvir, elbasvir/grazoprevir and sofosbuvir/ledipasvir without compromising efficacy, confirming our retrospective mo
Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection.
Flamm SL, Kort J, Marx SE, Strezewski J, Dylla DE, Bacon B, Curry MP, Tsai N, Wick N.
Advances in therapy. 2020 May;37(5)2267-2274.
Glecaprevir/pibrentasvir (G/P) was approved on 26 September 2019 by the US Food and Drug Administration for 8-week duration in treatment-naïve (TN) hepatitis C virus (HCV)-infected patients with compensated cirrhosis (CC). Evidence from the EXPEDITION-8 study demonstrated that 8 weeks of G/P achie
… Two patients were treated with 12 weeks of ombitasvir/paritaprevir/ritonavir, and the other patient was treated with 8 weeks of glecaprevir/pibrentasvir. …
USE MAVYRET is a prescription medicine used to treat adults and children 12 years of age and older or weighing at least 99 pounds (45 kilograms) with chronic (lasting a long time) hepatitis C virus (hep C): Genotypes (GT) 1, 2, 3, 4
Pibrentasvir is a direct acting antiviral agent and Hepatitis C virus (HCV) NS5A inhibitor that targets the the viral RNA replication and viron assembly. In combination with DB13879, pibrentastiv is a useful therapy for patients who ...